Serveur d'exploration sur le lymphœdème

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Activation of vascular endothelial growth factor receptor-3 and its downstream signaling promote cell survival under oxidative stress.

Identifieur interne : 003B92 ( PubMed/Checkpoint ); précédent : 003B91; suivant : 003B93

Activation of vascular endothelial growth factor receptor-3 and its downstream signaling promote cell survival under oxidative stress.

Auteurs : Jian Feng Wang [États-Unis] ; Xuefeng Zhang ; Jerome E. Groopman

Source :

RBID : pubmed:15102829

Descripteurs français

English descriptors

Abstract

Reactive oxygen species (ROS) mediate cell damage and have been implicated in the pathogenesis of diseases that involve endothelial injury. Cells possess antioxidant systems, including intracellular antioxidants and ROS scavenging enzymes, that control the redox state and prevent cell damage. In addition to intracellular antioxidants, certain growth factor receptors can be activated under oxidative stress and trigger downstream cell survival signaling cascades. Vascular endothelial growth factor receptor-3 (VEGFR-3) is a primary modulator of lymphatic endothelial proliferation and survival. Here, we provide evidence that activation of VEGFR-3 signaling in response to hydrogen peroxide (H(2)O(2)) promotes endothelial cell survival. Treatment with H(2)O(2) induced the tyrosine phosphorylation of VEGFR-3 and its association with the signaling adaptor proteins Shc, growth factor receptor binding protein 2, Sos, p85, SHP-2, and phospholipase C-gamma. Of note, a hereditary lymphoedema-linked mutant of VEGFR-3 was not phosphorylated by H(2)O(2) treatment. Isoforms of protein kinase C (PKC), alpha and delta, were also tyrosine-phosphorylated after H(2)O(2) stimulation. However, only the delta isoform of PKC was required for H(2)O(2)-induced phosphorylation of VEGFR-3. The tyrosine phosphorylation of VEGFR-3 or isoforms of PKC was completely inhibited by treatment with 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine, a specific inhibitor for Src family kinases, indicating that Src family kinases are upstream of PKC and VEGFR-3. Furthermore, expression of the wild-type but not the lymphoedema-linked mutant form of VEGFR-3 in porcine artery endothelial cells significantly enhanced the activation of Akt after H(2)O(2) stimulation. Consistent with these biochemical changes, we observed that expression and activation of the wild-type but not the mutant form of VEGFR-3 inhibited H(2)O(2)-induced apoptosis. These studies suggest that VEGFR-3 protects against oxidative damage in endothelial cells, and that patients with hereditary lymphoedema may be susceptible to ROS-induced cell damage.

DOI: 10.1074/jbc.M314015200
PubMed: 15102829


Affiliations:


Links toward previous steps (curation, corpus...)


Links to Exploration step

pubmed:15102829

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Activation of vascular endothelial growth factor receptor-3 and its downstream signaling promote cell survival under oxidative stress.</title>
<author>
<name sortKey="Wang, Jian Feng" sort="Wang, Jian Feng" uniqKey="Wang J" first="Jian Feng" last="Wang">Jian Feng Wang</name>
<affiliation wicri:level="1">
<nlm:affiliation>Division of Experimental Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Experimental Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215</wicri:regionArea>
<wicri:noRegion>Massachusetts 02215</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Zhang, Xuefeng" sort="Zhang, Xuefeng" uniqKey="Zhang X" first="Xuefeng" last="Zhang">Xuefeng Zhang</name>
</author>
<author>
<name sortKey="Groopman, Jerome E" sort="Groopman, Jerome E" uniqKey="Groopman J" first="Jerome E" last="Groopman">Jerome E. Groopman</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2004">2004</date>
<idno type="RBID">pubmed:15102829</idno>
<idno type="pmid">15102829</idno>
<idno type="doi">10.1074/jbc.M314015200</idno>
<idno type="wicri:Area/PubMed/Corpus">004019</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">004019</idno>
<idno type="wicri:Area/PubMed/Curation">004019</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">004019</idno>
<idno type="wicri:Area/PubMed/Checkpoint">004019</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">004019</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Activation of vascular endothelial growth factor receptor-3 and its downstream signaling promote cell survival under oxidative stress.</title>
<author>
<name sortKey="Wang, Jian Feng" sort="Wang, Jian Feng" uniqKey="Wang J" first="Jian Feng" last="Wang">Jian Feng Wang</name>
<affiliation wicri:level="1">
<nlm:affiliation>Division of Experimental Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Experimental Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215</wicri:regionArea>
<wicri:noRegion>Massachusetts 02215</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Zhang, Xuefeng" sort="Zhang, Xuefeng" uniqKey="Zhang X" first="Xuefeng" last="Zhang">Xuefeng Zhang</name>
</author>
<author>
<name sortKey="Groopman, Jerome E" sort="Groopman, Jerome E" uniqKey="Groopman J" first="Jerome E" last="Groopman">Jerome E. Groopman</name>
</author>
</analytic>
<series>
<title level="j">The Journal of biological chemistry</title>
<idno type="ISSN">0021-9258</idno>
<imprint>
<date when="2004" type="published">2004</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Cell Line</term>
<term>Cell Survival (physiology)</term>
<term>Endothelium, Vascular (cytology)</term>
<term>Enzyme Activation (drug effects)</term>
<term>Enzyme Inhibitors (pharmacology)</term>
<term>Humans</term>
<term>Hydrogen Peroxide (pharmacology)</term>
<term>Lymphedema (genetics)</term>
<term>Lymphedema (metabolism)</term>
<term>Mutation, Missense</term>
<term>Oncogene Protein v-akt</term>
<term>Oxidative Stress (drug effects)</term>
<term>Oxidative Stress (physiology)</term>
<term>Phosphoric Monoester Hydrolases (antagonists & inhibitors)</term>
<term>Phosphorylation</term>
<term>Protein Kinase C (antagonists & inhibitors)</term>
<term>Protein Kinase C (genetics)</term>
<term>Protein Kinase C (metabolism)</term>
<term>Pyrimidines (pharmacology)</term>
<term>Recombinant Proteins (genetics)</term>
<term>Recombinant Proteins (metabolism)</term>
<term>Retroviridae Proteins, Oncogenic (metabolism)</term>
<term>Signal Transduction</term>
<term>Tyrosine (metabolism)</term>
<term>Vanadates (pharmacology)</term>
<term>Vascular Endothelial Growth Factor Receptor-3 (genetics)</term>
<term>Vascular Endothelial Growth Factor Receptor-3 (metabolism)</term>
<term>Vascular Endothelial Growth Factor Receptor-3 (physiology)</term>
<term>src Homology Domains</term>
<term>src-Family Kinases (antagonists & inhibitors)</term>
<term>src-Family Kinases (genetics)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Activation enzymatique ()</term>
<term>Antienzymes (pharmacologie)</term>
<term>Domaine d'homologie SRC</term>
<term>Endothélium vasculaire (cytologie)</term>
<term>Humains</term>
<term>Lignée cellulaire</term>
<term>Lymphoedème (génétique)</term>
<term>Lymphoedème (métabolisme)</term>
<term>Mutation faux-sens</term>
<term>Peroxyde d'hydrogène (pharmacologie)</term>
<term>Phosphoric monoester hydrolases (antagonistes et inhibiteurs)</term>
<term>Phosphorylation</term>
<term>Protéine kinase C (antagonistes et inhibiteurs)</term>
<term>Protéine kinase C (génétique)</term>
<term>Protéine kinase C (métabolisme)</term>
<term>Protéine oncogène v-akt</term>
<term>Protéines oncogènes des retroviridae (métabolisme)</term>
<term>Protéines recombinantes (génétique)</term>
<term>Protéines recombinantes (métabolisme)</term>
<term>Pyrimidines (pharmacologie)</term>
<term>Récepteur-3 au facteur croissance endothéliale vasculaire (génétique)</term>
<term>Récepteur-3 au facteur croissance endothéliale vasculaire (métabolisme)</term>
<term>Récepteur-3 au facteur croissance endothéliale vasculaire (physiologie)</term>
<term>Stress oxydatif ()</term>
<term>Stress oxydatif (physiologie)</term>
<term>Survie cellulaire (physiologie)</term>
<term>Transduction du signal</term>
<term>Tyrosine (métabolisme)</term>
<term>Vanadates (pharmacologie)</term>
<term>src-Family kinases (antagonistes et inhibiteurs)</term>
<term>src-Family kinases (génétique)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en">
<term>Phosphoric Monoester Hydrolases</term>
<term>Protein Kinase C</term>
<term>src-Family Kinases</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en">
<term>Protein Kinase C</term>
<term>Recombinant Proteins</term>
<term>Vascular Endothelial Growth Factor Receptor-3</term>
<term>src-Family Kinases</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en">
<term>Protein Kinase C</term>
<term>Recombinant Proteins</term>
<term>Retroviridae Proteins, Oncogenic</term>
<term>Tyrosine</term>
<term>Vascular Endothelial Growth Factor Receptor-3</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en">
<term>Enzyme Inhibitors</term>
<term>Hydrogen Peroxide</term>
<term>Pyrimidines</term>
<term>Vanadates</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr">
<term>Phosphoric monoester hydrolases</term>
<term>Protéine kinase C</term>
<term>src-Family kinases</term>
</keywords>
<keywords scheme="MESH" qualifier="cytologie" xml:lang="fr">
<term>Endothélium vasculaire</term>
</keywords>
<keywords scheme="MESH" qualifier="cytology" xml:lang="en">
<term>Endothelium, Vascular</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en">
<term>Enzyme Activation</term>
<term>Oxidative Stress</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en">
<term>Lymphedema</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr">
<term>Lymphoedème</term>
<term>Protéine kinase C</term>
<term>Protéines recombinantes</term>
<term>Récepteur-3 au facteur croissance endothéliale vasculaire</term>
<term>src-Family kinases</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en">
<term>Lymphedema</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr">
<term>Lymphoedème</term>
<term>Protéine kinase C</term>
<term>Protéines oncogènes des retroviridae</term>
<term>Protéines recombinantes</term>
<term>Récepteur-3 au facteur croissance endothéliale vasculaire</term>
<term>Tyrosine</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr">
<term>Antienzymes</term>
<term>Peroxyde d'hydrogène</term>
<term>Pyrimidines</term>
<term>Vanadates</term>
</keywords>
<keywords scheme="MESH" qualifier="physiologie" xml:lang="fr">
<term>Récepteur-3 au facteur croissance endothéliale vasculaire</term>
<term>Stress oxydatif</term>
<term>Survie cellulaire</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en">
<term>Cell Survival</term>
<term>Oxidative Stress</term>
<term>Vascular Endothelial Growth Factor Receptor-3</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Cell Line</term>
<term>Humans</term>
<term>Mutation, Missense</term>
<term>Oncogene Protein v-akt</term>
<term>Phosphorylation</term>
<term>Signal Transduction</term>
<term>src Homology Domains</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Activation enzymatique</term>
<term>Domaine d'homologie SRC</term>
<term>Humains</term>
<term>Lignée cellulaire</term>
<term>Mutation faux-sens</term>
<term>Phosphorylation</term>
<term>Protéine oncogène v-akt</term>
<term>Stress oxydatif</term>
<term>Transduction du signal</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Reactive oxygen species (ROS) mediate cell damage and have been implicated in the pathogenesis of diseases that involve endothelial injury. Cells possess antioxidant systems, including intracellular antioxidants and ROS scavenging enzymes, that control the redox state and prevent cell damage. In addition to intracellular antioxidants, certain growth factor receptors can be activated under oxidative stress and trigger downstream cell survival signaling cascades. Vascular endothelial growth factor receptor-3 (VEGFR-3) is a primary modulator of lymphatic endothelial proliferation and survival. Here, we provide evidence that activation of VEGFR-3 signaling in response to hydrogen peroxide (H(2)O(2)) promotes endothelial cell survival. Treatment with H(2)O(2) induced the tyrosine phosphorylation of VEGFR-3 and its association with the signaling adaptor proteins Shc, growth factor receptor binding protein 2, Sos, p85, SHP-2, and phospholipase C-gamma. Of note, a hereditary lymphoedema-linked mutant of VEGFR-3 was not phosphorylated by H(2)O(2) treatment. Isoforms of protein kinase C (PKC), alpha and delta, were also tyrosine-phosphorylated after H(2)O(2) stimulation. However, only the delta isoform of PKC was required for H(2)O(2)-induced phosphorylation of VEGFR-3. The tyrosine phosphorylation of VEGFR-3 or isoforms of PKC was completely inhibited by treatment with 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine, a specific inhibitor for Src family kinases, indicating that Src family kinases are upstream of PKC and VEGFR-3. Furthermore, expression of the wild-type but not the lymphoedema-linked mutant form of VEGFR-3 in porcine artery endothelial cells significantly enhanced the activation of Akt after H(2)O(2) stimulation. Consistent with these biochemical changes, we observed that expression and activation of the wild-type but not the mutant form of VEGFR-3 inhibited H(2)O(2)-induced apoptosis. These studies suggest that VEGFR-3 protects against oxidative damage in endothelial cells, and that patients with hereditary lymphoedema may be susceptible to ROS-induced cell damage.</div>
</front>
</TEI>
<pubmed>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">15102829</PMID>
<DateCreated>
<Year>2004</Year>
<Month>06</Month>
<Day>21</Day>
</DateCreated>
<DateCompleted>
<Year>2004</Year>
<Month>08</Month>
<Day>13</Day>
</DateCompleted>
<DateRevised>
<Year>2016</Year>
<Month>11</Month>
<Day>24</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">0021-9258</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>279</Volume>
<Issue>26</Issue>
<PubDate>
<Year>2004</Year>
<Month>Jun</Month>
<Day>25</Day>
</PubDate>
</JournalIssue>
<Title>The Journal of biological chemistry</Title>
<ISOAbbreviation>J. Biol. Chem.</ISOAbbreviation>
</Journal>
<ArticleTitle>Activation of vascular endothelial growth factor receptor-3 and its downstream signaling promote cell survival under oxidative stress.</ArticleTitle>
<Pagination>
<MedlinePgn>27088-97</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Reactive oxygen species (ROS) mediate cell damage and have been implicated in the pathogenesis of diseases that involve endothelial injury. Cells possess antioxidant systems, including intracellular antioxidants and ROS scavenging enzymes, that control the redox state and prevent cell damage. In addition to intracellular antioxidants, certain growth factor receptors can be activated under oxidative stress and trigger downstream cell survival signaling cascades. Vascular endothelial growth factor receptor-3 (VEGFR-3) is a primary modulator of lymphatic endothelial proliferation and survival. Here, we provide evidence that activation of VEGFR-3 signaling in response to hydrogen peroxide (H(2)O(2)) promotes endothelial cell survival. Treatment with H(2)O(2) induced the tyrosine phosphorylation of VEGFR-3 and its association with the signaling adaptor proteins Shc, growth factor receptor binding protein 2, Sos, p85, SHP-2, and phospholipase C-gamma. Of note, a hereditary lymphoedema-linked mutant of VEGFR-3 was not phosphorylated by H(2)O(2) treatment. Isoforms of protein kinase C (PKC), alpha and delta, were also tyrosine-phosphorylated after H(2)O(2) stimulation. However, only the delta isoform of PKC was required for H(2)O(2)-induced phosphorylation of VEGFR-3. The tyrosine phosphorylation of VEGFR-3 or isoforms of PKC was completely inhibited by treatment with 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine, a specific inhibitor for Src family kinases, indicating that Src family kinases are upstream of PKC and VEGFR-3. Furthermore, expression of the wild-type but not the lymphoedema-linked mutant form of VEGFR-3 in porcine artery endothelial cells significantly enhanced the activation of Akt after H(2)O(2) stimulation. Consistent with these biochemical changes, we observed that expression and activation of the wild-type but not the mutant form of VEGFR-3 inhibited H(2)O(2)-induced apoptosis. These studies suggest that VEGFR-3 protects against oxidative damage in endothelial cells, and that patients with hereditary lymphoedema may be susceptible to ROS-induced cell damage.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Jian Feng</ForeName>
<Initials>JF</Initials>
<AffiliationInfo>
<Affiliation>Division of Experimental Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhang</LastName>
<ForeName>Xuefeng</ForeName>
<Initials>X</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Groopman</LastName>
<ForeName>Jerome E</ForeName>
<Initials>JE</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>R01HL61940</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2004</Year>
<Month>04</Month>
<Day>21</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Biol Chem</MedlineTA>
<NlmUniqueID>2985121R</NlmUniqueID>
<ISSNLinking>0021-9258</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C412373">AG 1879</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015682">Retroviridae Proteins, Oncogenic</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>3WHH0066W5</RegistryNumber>
<NameOfSubstance UI="D014638">Vanadates</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>42HK56048U</RegistryNumber>
<NameOfSubstance UI="D014443">Tyrosine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>BBX060AN9V</RegistryNumber>
<NameOfSubstance UI="D006861">Hydrogen Peroxide</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D040321">Vascular Endothelial Growth Factor Receptor-3</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.2</RegistryNumber>
<NameOfSubstance UI="D019061">src-Family Kinases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D051058">Oncogene Protein v-akt</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.13</RegistryNumber>
<NameOfSubstance UI="D011493">Protein Kinase C</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.1.3.2</RegistryNumber>
<NameOfSubstance UI="D010744">Phosphoric Monoester Hydrolases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D004730" MajorTopicYN="N">Endothelium, Vascular</DescriptorName>
<QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D004789" MajorTopicYN="N">Enzyme Activation</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D006861" MajorTopicYN="N">Hydrogen Peroxide</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008209" MajorTopicYN="N">Lymphedema</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D020125" MajorTopicYN="N">Mutation, Missense</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D051058" MajorTopicYN="N">Oncogene Protein v-akt</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D010744" MajorTopicYN="N">Phosphoric Monoester Hydrolases</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D011493" MajorTopicYN="N">Protein Kinase C</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D011743" MajorTopicYN="N">Pyrimidines</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D015682" MajorTopicYN="N">Retroviridae Proteins, Oncogenic</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D014443" MajorTopicYN="N">Tyrosine</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D014638" MajorTopicYN="N">Vanadates</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D040321" MajorTopicYN="N">Vascular Endothelial Growth Factor Receptor-3</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D018909" MajorTopicYN="N">src Homology Domains</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D019061" MajorTopicYN="N">src-Family Kinases</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="pubmed">
<Year>2004</Year>
<Month>4</Month>
<Day>23</Day>
<Hour>5</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2004</Year>
<Month>8</Month>
<Day>17</Day>
<Hour>10</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2004</Year>
<Month>4</Month>
<Day>23</Day>
<Hour>5</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">15102829</ArticleId>
<ArticleId IdType="doi">10.1074/jbc.M314015200</ArticleId>
<ArticleId IdType="pii">M314015200</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations>
<list>
<country>
<li>États-Unis</li>
</country>
</list>
<tree>
<noCountry>
<name sortKey="Groopman, Jerome E" sort="Groopman, Jerome E" uniqKey="Groopman J" first="Jerome E" last="Groopman">Jerome E. Groopman</name>
<name sortKey="Zhang, Xuefeng" sort="Zhang, Xuefeng" uniqKey="Zhang X" first="Xuefeng" last="Zhang">Xuefeng Zhang</name>
</noCountry>
<country name="États-Unis">
<noRegion>
<name sortKey="Wang, Jian Feng" sort="Wang, Jian Feng" uniqKey="Wang J" first="Jian Feng" last="Wang">Jian Feng Wang</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003B92 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 003B92 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    RBID
   |clé=     pubmed:15102829
   |texte=   Activation of vascular endothelial growth factor receptor-3 and its downstream signaling promote cell survival under oxidative stress.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i   -Sk "pubmed:15102829" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a LymphedemaV1 

Wicri

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024